|
1.
The appointment of Dr Lee was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee. The Committee conducted an extensive search and
selection process for this appointment, using an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a diverse
list of candidates who were approached, evaluated and interviewed
against an agreed set of criteria aligned to the Board's target
skills matrix. The Board satisfied itself that Dr Lee had the
experience and time available to carry out the role.
|
|
2.
The Board has determined that Dr Lee is an independent
Non-Executive Director in accordance with the UK Corporate
Governance Code.
|
|
3.
Dr Lee will receive the standard basic fee for a Non-Executive
Director of £118,352 per annum (including travel allowance).
She will also receive fees of £30,000 per annum as a
scientific and medical expert. Dr Lee will be required to build
towards a share ownership requirement of GSK shares in accordance
with the Company's shareholder approved Non-Executive remuneration
policy.
|
|
4.
"Scientific and Medical Expert" - The Board designates
Non-Executive Directors whose expertise or backgrounds as renowned
medical scientists, researchers, or physicians mean that they can
bring scientific or industry expertise to the Board's
deliberations.
|
|
5.
Dr Lee will become a member of the Science and Corporate
Responsibility committees on her appointment.
|
|
6.
Dr Lee does not have a service contract. She has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
|
7.
There are no further disclosures to be made in respect of Dr Lee's
appointment under Listing Rule 9.6.13R.
|
|
8.
As of 4 March 2024, the Board of GSK will comprise:
|
Sir
Jonathan Symonds
|
Non-Executive
Chair
|
Emma
Walmsley
|
Chief
Executive Officer
|
Julie
Brown
|
Chief
Financial Officer
|
Charles
Bancroft
|
Senior
Independent Non-Executive Director
|
Elizabeth McKee
Anderson
|
Independent
Non-Executive Director
|
Dr Hal
Barron
|
Non-Executive
Director
|
Dr Anne
Beal
|
Independent
Non-Executive Director
|
Wendy
Becker
|
Independent
Non-Executive Director
|
Dr Hal
Dietz
|
Independent
Non-Executive Director
|
Dr
Jesse Goodman
|
Independent
Non-Executive Director
|
Dr
Jeannie Lee
|
Independent
Non-Executive Director
|
Urs
Rohner
|
Independent
Non-Executive Director
|
Dr
Vishal Sikka
|
Independent
Non-Executive Director
|
GSK enquiries
|
|
|
||
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
|
|
|
|
|
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: February
29, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|